| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| A1020-100 | Anti-human EGFR | 100µg | $185 | Order |
| A1020-200 | Anti-human EGFR | 200µg | $325 | Order |
| Catalog Number | A1020 |
|---|---|
| Product Name | Anti-human EGFR |
| Source | Recombinant anti-human EGFR mAb produced in HEK293 cells |
| Clone | Cetuximab |
| Species Reactivity | Human |
| Isotype | Human IgG1 |
| Purity | >95% |
| Formulation | 50mM Na Acetate, pH5.2. Sterile |
| Stability & Storage | 1 month at 4oC; 12 months at <-20oC; Avoid repeated freeze-thaw |
| Protein Aggregation | Not obvious on SDS-PAGE |
| Application | Flow cytometry, ELISA, cell-based assay |
| Product Datasheet: | Download PDF |
Detection of EGFR expression on human colorectal adenocarcinoma cell line HCT-15 by flow cytometry. Anti-human EGFR antibody (Cat. #A1020) was incubated with human HCT-15 cells, followed by staining with PE-anti-mouse IgG.
Epidermal growth factor receptor (EGFR), also known as ErbB-1, is a transmembrane receptor protein that belongs to the receptor tyrosine kinase family. It is encoded by the EGFR gene and is expressed in various tissues, including the epithelial cells of the skin, lung, gastrointestinal tract, and brain. EGFR is involved in several cellular processes, including cell growth, proliferation, differentiation, and survival, through activation of downstream signaling pathways such as the MAPK/ERK and PI3K/Akt pathways. However, dysregulation of EGFR signaling has been linked to cancer development and progression in various cancers, including non-small cell lung, head and neck, colorectal, and pancreatic cancers. Therefore, EGFR has become an attractive therapeutic target in oncology. Small molecular inhibitors, such as gefitinib, erlotinib, and afatinib, and monoclonal antibodies, such as cetuximab and panitumumab, have been developed to target EGFR for the treatment of various cancers, particularly in patients with EGFR mutations or overexpression.
Carpenter G. Annual Review of Biochemistry. 56: 881–914, 1987.
Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., Tarnawski, A. S. Nature Med. 8: 289-293, 2002.
Reynolds, F. H., Jr., Todaro, G. J., Fryling, C., Stephenson, J. R. Nature. 292: 259-262, 1981.
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H. Proc. Nat. Acad. Sci. 101: 13306-13311, 2004.
Nakamura JL. Expert Opinion on Therapeutic Targets. 11 (4): 463–72, 2007.